ClinicalTrials.gg
CompletedNCT00784862Updated May 15, 2009

ATAC - Pharmacokinetics (PK) Sub-Protocol

A Phase 3 interventional study of Anastrozole and Tamoxifen in Breast Cancer, sponsored by AstraZeneca. Completed. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2009-05-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9,358
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies testing anastrozole in Breast Neoplasms — 17 open to participants now, 28 under way, 10 of them phase 3. Anastrozole · Breast Neoplasms.

Enrollment
Largest of 109
9,358 · median 148
Started
1998
with 1 other
Phase 3
38 of 111
5 open now
Registered
39th of 111
by date
Lead sponsor
16 of 111
AstraZeneca

Among the 111 studies testing anastrozole in Breast Neoplasms, this one has the largest enrollment of the 109 interventional ones that give a count, is one of 2 that started in 1998, is one of 38 in phase 3, and was the 39th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 111 studies testing anastrozole in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About anastrozole

Anastrozole: first FDA approval 1995 (ARIMIDEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 45 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing anastrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

To assess the effect of ARIMIDEX on the pharmacokinetics of tamoxifen and the effects of tamoxifen on the pharmacokinetics of ARIMIDEX..

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for entry into the main ATAC trial 1033IL/0029
  • Patients must have been taking ATAC trial medication for at least 3 months (i.e. patients must have reached at least visit 2 of the main ATAC study)
  • Patients should be taking their medication in the mornings for at least 3 months
  • Patients must be 100% compliant over the preceding fourteen days

Exclusion criteria

Exclusion Criteria:

  • Excluded from entry into the main ATAC trial (1033IL/0029)
  • Patients whose concurrent treatment includes diazepam or drugs which might affect tamoxifen steady state levels or hormone status. These include ketoconazole (antifungal) or related compounds
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
9,358 participants (actual)

Study arms

  • Active comparator
    1

    Arimidex 1mg + Nolvadex placebo

    Drug: Anastrozole

  • Active comparator
    2

    Arimidex placebo + Nolvadex 20mg

    Drug: Anastrozole · Drug: Tamoxifen

  • Active comparator
    3

    Arimidex 1mg + Nolvadex 20mg

    Drug: Tamoxifen

Interventions

  • 1mg, orally, once daily

    Also known as: Arimidex

  • 20mg, orally, once daily

    Also known as: Nolvadex

06

What researchers measure

Primary outcomes

  1. Steady state plasma trough concentrations of tamoxifen, desmethyltamoxifen and anastrozole

    Time frame: 24±4 hours after previous dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1998 and a completion of Mar 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2008
First posted
Nov 4, 2008
Start
Jun 1998
CompletionActual
Mar 1999
Last update
May 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00784862
Lead sponsor
AstraZeneca
First posted
Nov 4, 2008
Start date
Jun 1998
Completion
Mar 1999
Last update
May 15, 2009

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Tamoxifen

Start the discussion